Blood CancerArchives
Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan
Blood Cancer 1 min.
Venetoclax (VEN)-based regimens are widely used for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, but VEN dosing patterns and their relation to treatment persistence are not well described. We conducted a retrospective longitudinal study using de-identified...
Long non-coding RNAs and survival outcomes in chronic lymphocytic leukemia
Blood Cancer 1 min.
Chronic lymphocytic leukemia (CLL) is a highly heterogeneous hematological malignancy characterized by pronounced differences in clinical course and genetic . While research has historically focused on alterations in protein-coding genes, it is increasingly evident that the non-coding transcriptome plays...
Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia
Blood Cancer 1 min.
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder typically managed with BCR::ABL1 tyrosine kinase inhibitors (TKI). However, it can progress from chronic phase (CML-CP) to blast phase (CML-BP), during which BCR::ABL1 kinase domain (KD) genetic variants (e.g., T315I, Y253H) and aberrant...
Asparaginase activity levels and toxicity in children and adolescents with acute lymphoblastic leukemia
Blood Cancer 1 min.
Asparaginase (ASP) is a critical treatment component of acute lymphoblastic leukemia (ALL), yet associated with potentially severe complications. We assessed whether serum asparaginase activity (SAA) is associated with development of venous thrombosis, acute pancreatitis, bleeding and/or hypersensitivity...
Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways
Blood Cancer 1 min.
Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy characterized by the presence of the Philadelphia chromosome, which generates the constitutively active BCR::ABL1 tyrosine kinase, driving uncontrolled myeloid proliferation. Although BCR::ABL1-targeted tyrosine kinase inhibitors (TKIs)...
